Harnessing the power of microRNAs as prognostic biomarkers in acute heart failure
2017; Elsevier BV; Volume: 20; Issue: 1 Linguagem: Inglês
10.1002/ejhf.993
ISSN1879-0844
Autores Tópico(s)Extracellular vesicles in disease
ResumoEuropean Journal of Heart FailureVolume 20, Issue 1 p. 97-99 Editorial CommentFree Access Harnessing the power of microRNAs as prognostic biomarkers in acute heart failure Lee Lee Wong, Lee Lee Wong Cardiovascular Research Institute, National University Health System, Singapore Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, SingaporeSearch for more papers by this authorArthur Mark Richards, Corresponding Author Arthur Mark Richards mdcarthu@nus.edu.sg Cardiovascular Research Institute, National University Health System, Singapore Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore Cardiac Department, National University Health System, Singapore Christchurch Heart Institute, University of Otago, Christchurch, New Zealand Corresponding author.National University Health System, Singapore, 1E Kent Ridge Road, 119228 Singapore. Tel: +64 3 3641116, Fax: +64 3 3641115, Email: mdcarthu@nus.edu.sgSearch for more papers by this author Lee Lee Wong, Lee Lee Wong Cardiovascular Research Institute, National University Health System, Singapore Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, SingaporeSearch for more papers by this authorArthur Mark Richards, Corresponding Author Arthur Mark Richards mdcarthu@nus.edu.sg Cardiovascular Research Institute, National University Health System, Singapore Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore Cardiac Department, National University Health System, Singapore Christchurch Heart Institute, University of Otago, Christchurch, New Zealand Corresponding author.National University Health System, Singapore, 1E Kent Ridge Road, 119228 Singapore. Tel: +64 3 3641116, Fax: +64 3 3641115, Email: mdcarthu@nus.edu.sgSearch for more papers by this author First published: 25 September 2017 https://doi.org/10.1002/ejhf.993Citations: 1 The opinions expressed in this article are not necessarily those of the Editors of the European Journal of Heart Failure or of the European Society of Cardiology. doi: 10.1002/ejhf.950 AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat This article refers to 'Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure' by N. van Boven et al., published in this issue on pages 89–96. The discovery of microRNA over 20 years ago coupled with their stability in plasma has triggered investigation of circulating microRNAs as candidate biomarkers and/or as therapeutic targets in various diseases including heart failure. A growing body of evidence supports microRNAs as ubiquitous and key players in cellular function with regulatory roles in cardiac hypertrophy and fibrosis and in the deranged neurohormonal regulation of the circulation observed in heart failure. MicroRNAs add a layer of complexity to the response to cardiac injury or overload and to our understanding of how changes in gene network expression and related signalling pathways are regulated in heart disease. The plethora of microRNAs reported also point to many potential therapeutic targets for the amelioration of cardiac injury. Relatively few reports have addressed microRNAs as diagnostic and/or prognostic indicators in acute heart failure. Thus far, seven published reports focus on the use of microRNAs in prognosis and/or diagnosis in acute heart failure (Table 1).1-7 Table 1. Summary of reported serum/plasma microRNA biomarkers for acute heart failure Author Study cohort Platform used miRNA identified Xiao et al.1 96 AHF and 1-year follow-up miR-30d measurement by qRT-PCR and cel-39 was used as internal control miR-30d as prognostic marker at 1 year all-cause mortality in AHF Vegter et al.2 100 AHF at baseline and 48 h Customized 15 miRNAs and miR-30a-5p, miR-194-5p were used as reference genes Correlation study on miR-16-5p to C-reactive protein, miR-106a-5p to creatinine, miR-223-3p to growth differentiation factor 15, miR-652-3p to soluble ST2, miR-199a-3p to procalcitonin and galectin-3 and miR-18a-5p to procalcitonin. 16 protein biomarkers and 12 AHF-specific miRNAs predictive of worse clinical outcome at 180-day mortality Ovchinnikova et al.3 Discovery: 10 AHF, 10 CHF, 10 healthy controls with 6-month follow-up Validation: 9 AHF, 10 CHF, 9 COPD and 17 controls Extended cohort: 100 AHF at admission, 24 h, 48 h and day 7 qRT-PCR serum/plasma focus panel (375 miRNAs) 12 miRNAs decreased in AHF vs. CHF vs. COPD vs. controls, 7 miRNAs (let-7i-5p, miR-18a-5p, miR-18b-5p, miR-223-3p, miR-301a-3p, miR-423-5p miR-652-3p) predictive for 180-day mortality Seronde et al.4 Discovery: 236 AHF and 58 non-AHF, 44 stable CHF Validation: 711 AHF qRT-PCR on 5 miRNAs, normalized using spike-in controls miR-1, -126, -423-5p lower levels in AHF 423-5p associated with poor long-term outcome (1 year) Bruno et al.5 98 AHF, 17 with worsening renal function at day 3 qRT-PCR on 12 miRNAs, normalized against miR-30a-5p and 194-5p miR-199a-3p predictor for worsening of renal function in AHF Ellis et al.6 Discovery: 32 AHF, 15 COPD and 14 controls Validation: 44 AHF, 32 COPD, 59 other breathless and 15 controls qRT-PCR miRNA panel, normalized against miR-20a, miR-106b, miR-363 and miR-140-3p Four miR panel—miR-103, miR-142-3p, miR-30b and miR-342-3p—combined with NT-proBNP to detect HF from controls, COPD and others Tijsen et al.7 Discovery: 12 AHF, 12 controls Validation: 30 AHF, 20 non-AHF and 30 controls miRNA array for discovery and RT-PCR for validation, normalized against miR-1249 miR-423-5p predictor of HF (multivariate logistic regression including age and sex) with AUC of 0.91 miR-18b*, -129-5p, -1254, -675, -622 increased in AHF vs. controls AHF, acute heart failure; AUC, area under the curve; CHF, chronic heart failure; COPD, chronic obstructive pulmonary disease; HF, heart failure; miRNA, microRNA; NT-proBNP, N-terminal pro-B-type natriuretic peptide; qRT-PCR, quantitative reverse transcriptase polymerase chain reaction. In the current issue of the Journal, van Boven et al.8 have assessed the prognostic performance of 12 serial measured circulating microRNAs for prediction of 1-year outcomes in the TRIUMPH acute heart failure cohort. Both baseline and serial measurements of miR-1306-5p have significant prognostic power independent of other predictors including N-terminal pro-B-type natriuretic peptide (NT-proBNP). The findings with respect to miR-1306-5p were first developed from trans-cardiac blood sampling and tissue studies in an instrumented swine model. Demonstration of a cardiac source for this microRNA in the pig model was followed up with serial measurements of miR-1306-5p and 11 other microRNAs (previously reported as cardiac-enriched and/or muscle-specific) in 475 participants in TRIUMPH. The selection of microRNAs was rationale but clearly leaves a large number of other microRNA candidates unexplored. Notably, the investigators report very high rates of invalid or undetectable results for both miR-1306-5p and other heart-enriched microRNAs indicating the exploratory nature of this report and the challenges remaining before any prognostic microRNA panel can be introduced into routine clinical use. Given the large RNA sequencing data set generated and the previously reported studies (Table 1), the authors selected a very limited array of microRNAs for their exploratory clinical screening. Further work could usefully extend the selection of microRNAs to include more of those previously reported in acute heart failure (Table 1). Van Boven et al.8 are first to use normalize their data according to levels of plasma miR-486-5p. The authors reported that miR-486-5p was highly abundant (constituting 92.5–97% of all sequencing reads) in plasma samples. Notably, to date, there is no consensus on optimal normalizing strategies or choice of endogenous control to be used in studies of circulating microRNAs. A search on 'miR-486-5p' suggested this microRNA is significantly associated with body mass index and other measurements of obesity, particularly in children,9 and it is also correlated with ventricular contractility in the setting of right ventricular dysfunction.10 More evidence is required to warrant the use of miR-486-5p as a normalizer or endogenous control. It remains a challenge to establish the gold standard for normalizing circulating microRNA levels to ensure accuracy and reproducibility. For both the association of miR-1306-5p with prognosis and the use of miR-486-5p for normalization, the current findings require validation in further independent acute heart failure cohorts. Investigation of new candidate prognostic biomarkers (singly or in combination) requires assessment of what they might add to our existing predictive tools. The B-type natriuretic peptides, BNP and NT-proBNP,11 are established in this role and other peptide candidates include mid-regional pro-atrial natriuretic peptide (MR-proANP)12 and mid-regional pro-adrenomedullin (MR-proADM),13 which are known to add prognostic value to BNP and/or NT-proBNP.14 Other circulating markers with acknowledged independent prognostic power in acute heart failure include endothelin-1, soluble ST2, highly-sensitive troponin, growth differentiation factor 15, high-sensitivity C-reactive protein, galectin-3, and cystatin-C. Van Boven et al.8 report single and serial measures of miR-1306-5p are independently associated with all cause-mortality and heart failure hospitalization. However, miR-1306-5p does not add to the area under the curve, net reallocation improvement (NRI) or integrated discrimination improvement (IDI) for prognosis in models which already incorporate NT-proBNP. This further confirms, despite the likely pathophysiological importance of microRNAs in heart failure, their measurement is not yet warranted for 'prime time' clinical application. Given the prognostic performance of miR-1306-5p, the function of this particular microRNA in the setting of acute heart failure is of potential importance. The absence of any mechanistic insights is one tantalising deficit in the current report. What mechanisms underlay the association of circulating miR-1306-5p with disease progression in swine undergoing aortic banding or with prognosis in the human TRIUMPH participants? An in silico search using two microRNA-target prediction databases (miRDB and TargetScan) yielded >200 potential mRNA targets for miR-1306-5p with 52 targets appearing in both databases. These include aquaporin 1, which functions as a transmembrane channel with a role in water homeostasis,15 and HEY2 regulating cardiac electrical activity16 with variants associated with Brugada syndrome and high risk of sudden cardiac death. Further in vitro and in vivo functional studies are required to elucidate the role of miR-1306-5p. MicroRNAs have great potential to be developed as prognostic biomarkers. Much progress has been made but we are still far from any routine clinical application in heart failure. This paper adds new knowledge about miR-1306-5p and the report reflects a necessary pioneering step highlighting the many challenges on the way to defining the role of circulating microRNA in the understanding and management of acute heart failure. Conflict of interest: none declared. References 1Xiao J, Gao R, Bei Y, Zhou Q, Zhou Y, Zhang H, Jin M, Wei S, Wang K, Xu X, Yao W, Xu D, Zhou F, Jiang J, Li X, Das S. Circulating miR-30d predicts survival in patients with acute heart failure. Cell Physiol Biochem 2017; 41: 865– 874. 2Vegter EL, Schmitter D, Hagemeijer Y, Ovchinnikova ES, van der Harst P, Teerlink JR, O'Connor CM, Metra M, Davison BA, Bloomfield D, Cotter G, Cleland JG, Givertz MM, Ponikowski P, van Veldhuisen DJ, van der Meer P, Berezikov E, Voors AA, Khan MA. Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. Int J Cardiol 2016; 224: 231– 239. 3Ovchinnikova ES, Schmitter D, Vegter EL, Ter Maaten JM, Valente MA, Liu LC, van der Harst P, Pinto YM, de Boer RA, Meyer S, Teerlink JR, O'Connor CM, Metra M, Davison BA, Bloomfield DM, Cotter G, Cleland JG, Mebazaa A, Laribi S, Givertz MM, Ponikowski P, van der Meer P, van Veldhuisen DJ, Voors AA, Berezikov E. Signature of circulating microRNAs in patients with acute heart failure. Eur J Heart Fail 2016; 18: 414– 423. 4Seronde MF, Vausort M, Gayat E, Goretti E, Ng LL, Squire IB, Vodovar N, Sadoune M, Samuel JL, Thum T, Solal AC, Laribi S, Plaisance P, Wagner DR, Mebazaa A, Devaux Y; GREAT Network. Circulating microRNAs and outcome in patients with acute heart failure. PLoS One 2015; 10:e0142237. 5Bruno N, ter Maaten JM, Ovchinnikova ES, Vegter EL, Valente MA, van der Meer P, de Boer RA, van der Harst P, Schmitter D, Metra M, O'Connor CM, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Dittrich HC, Pinto YM, van Veldhuisen DJ, Hillege HL, Berezikov E, Voors AA. MicroRNAs relate to early worsening of renal function in patients with acute heart failure. Int J Cardiol 2016; 203: 564– 569. 6Ellis KL, Cameron VA, Troughton RW, Frampton CM, Ellmers LJ, Richards AM. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail 2013; 15: 1138– 1147. 7Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, Pinto YM. MiR423-5p as a circulating biomarker for heart failure. Circ Res 2010; 106: 1035– 1039. 8van Boven N, Kardys I, van Vark LC, Akkerhuis KM, de Ronde MV, Khan MA, Merkus D, Liu Z, Voors AA, Asselbergs FW, van den Bos EJ, Boersma E, Hillege H, Duncker DJ, Pinto YM, Postmus D. Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure. Eur J Heart Fail 2017. doi: 10.1002/ejhf.950. 9Prats-Puig A, Ortega FJ, Mercader JM, Moreno-Navarrete JM, Moreno M, Bonet N, Ricart W, Lopez-Bermejo A, Fernandez-Real JM. Changes in circulating microRNAs are associated with childhood obesity. J Clin Endocrinol Metab 2013; 98: E1655– E1660. 10Lai CT, Ng EK, Chow PC, Kwong A, Cheung YF. Circulating microRNA expression profile and systemic right ventricular function in adults after atrial switch operation for complete transposition of the great arteries. BMC Cardiovasc Disord 2013; 13: 73. 11Noveanu M, Breidthardt T, Potocki M, Reichlin T, Twerenbold R, Uthoff H, Socrates T, Arenja N, Reiter M, Meissner J, Heinisch C, Stalder S, Mueller C. Direct comparison of serial B-type natriuretic peptide and NT-proBNP levels for prediction of short- and long-term outcome in acute decompensated heart failure. Crit Crit Care 2011; 15: R1. 12Seronde MF, Gayat E, Logeart D, Lassus J, Laribi S, Boukef R, Sibellas F, Launay JM, Manivet P, Sadoune M, Nouira S, Solal AC, Mebazaa A; GREAT Network. Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure. Int J Cardiol 2013; 168: 3404– 3411. 13Pervez MO, Lyngbakken MN, Myhre PL, Brynildsen J, Langsjoen EC, Hoiseth AD, Christensen G, Omland T, Rosjo H. Mid-regional pro-adrenomedullin in patients with acute dyspnea: data from the Akershus Cardiac Examination (ACE) 2 Study. Clin Biochem 2017; 50: 394– 400. 14Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng L, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Terracciano G, Kremastinos D, Hartmann O, von Haehling S, Bergmann A, Morgenthaler NG, Anker SD. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010; 55: 2062– 2076. 15Laski ME, Pressley TA. Aquaporin mediated water flux as a target for diuretic development. Semin Nephrol 1999; 19: 533– 550. 16Bezzina CR, Barc J, Mizusawa Y, Remme CA, Gourraud JB, Simonet F, Verkerk AO, Schwartz PJ, Crotti L, Dagradi F, Guicheney P, Fressart V, Leenhardt A, Antzelevitch C, Bartkowiak S, Borggrefe M, Schimpf R, Schulze-Bahr E, Zumhagen S, Behr ER, Bastiaenen R, Tfelt-Hansen J, Olesen MS, Kaab S, Beckmann BM, Weeke P, Watanabe H, Endo N, Minamino T, Horie M, Ohno S, Hasegawa K, Makita N, Nogami A, Shimizu W, Aiba T, Froguel P, Balkau B, Lantieri O, Torchio M, Wiese C, Weber D, Wolswinkel R, Coronel R, Boukens BJ, Bezieau S, Charpentier E, Chatel S, Despres A, Gros F, Kyndt F, Lecointe S, Lindenbaum P, Portero V, Violleau J, Gessler M, Tan HL, Roden DM, Christoffels VM, Le Marec H, Wilde AA, Probst V, Schott JJ, Dina C, Redon R. Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet 2013; 45: 1044– 1049. Citing Literature Volume20, Issue1January 2018Pages 97-99 ReferencesRelatedInformation
Referência(s)